TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Test and Treat Strategy in New HIV Diagnosis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old.~2. Having confirmed HIV-1 positive test.~3. Patients not previously treated with antiretroviral treatment (post-exposure prophylaxis will be allowed if not done in the previous 6 months).~4. Clinically stable patients, in the opinion of the investigator, at the time of inclusion.~5. Women of child-bearing potential\* must have a negative pregnancy test in urine before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: hormonal contraceptive methods intrauterine device, bilateral tubal occlusion, vasectomized partner or sexual abstinence.~6. Written informed consent.~Exclusion Criteria:~1. Pregnant or breastfeeding women at the time of the study inclusion or anticipating pregnancy during the follow-up period.~2. Suspicion of an active opportunistic infection that defers initiating antiretroviral treatment \> 7 days since HIV confirmation.~3. Known hypersensitivity or intolerance of any of the components of Biktarvy®.~4. Patients on treatment with any prohibited medication (see section 5.2: Concomitant, nonpermitted and permitted medication).~5. Any condition which, in the opinion of the principal investigator, may interfere with adequate understanding, cooperation or compliance with the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biktarvy (Type: EXPERIMENTAL): This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study for Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between 18-85 years old~* Must have been diagnosed by his/her doctor with overactive bladder at least 6 months ago~* Must weigh at least 50 kg (110 lbs)~* Must be willing and able to record information regarding bladder function into a diary (provided)~* Must be willing and able to complete the entire course of the study~Exclusion Criteria:~* Cannot currently be catheterizing as a way to control incontinence~* Must not have used botulinum toxin type A or any other botulinum toxin previously for any condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (normal saline) injected into detrusor on Day 1
- BOTOX 50 U (Type: EXPERIMENTAL): botulinum toxin Type A 50 U injected into detrusor on Day 1
- BOTOX 100 U (Type: EXPERIMENTAL): botulinum toxin Type A 100 U injected into detrusor on Day 1
- BOTOX 150 U (Type: EXPERIMENTAL): botulinum toxin Type A 150 U injected into detrusor on Day 1
- BOTOX 200 U (Type: EXPERIMENTAL): botulinum toxin Type A 200 U injected into detrusor on Day 1
- BOTOX 300 U (Type: EXPERIMENTAL): botulinum toxin Type A 300 U injected into detrusor on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Interventions in Children With Attention Deficit/Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Attention deficit hyperactivity disorder DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) diagnosis~* Score above 32 on the Swanson, Nolan, and Pelham-IV scale~* Child is registered in a school or day care center~* Children without the use of stimulants or any psychotropic in the last 30 days~Exclusion Criteria:~* Intelligence quotient \<70~* The presence of clinical condition or history of neurological disorder or head trauma with conscience loss~* The presence of affective and psychotic disorders, as well as autism spectrum disorders.~* The absence of a legal representative with the capacity to understand the study objectives and the instructions related to its participation.

- Gender: ALL
- Minimum Age: 47 Months
- Maximum Age: 71 Months
- Healthy Volunteers: f

Study Arms:
- Methylphenidate-psychoeducational group (Type: EXPERIMENTAL): Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments) and weekly psychoeducational groups for parents during 8 weeks.
- Parental training-placebo pill (Type: EXPERIMENTAL): Weekly parental training conducted by behavioral psychologists and placebo pill during 8 weeks.
- Psychoeducational group-placebo pill (Type: PLACEBO_COMPARATOR): Weekly psychoeducational groups for parents and placebo pill during 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients over 18 years of age~* Patients presenting with a lung or pleural nodule or mass presumed to be resectable on pre-operative assessment~* Good operative candidate~* Subject capable of giving informed consent and participating in the process of consent~Exclusion Criteria:~* Pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hCG) within 72 hours of surgery~* Patients with a history of anaphylactic reactions to Folate-FITC or insects~* At-risk patient populations:~  * Homeless patients~ * Patients with drug or alcohol dependence~ * Children and neonates~ * Patients unable to participate in the consent process

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Injection of EC17 (Type: EXPERIMENTAL): The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genotype 1 hepatitis C infection (confirmed at screening)~* Have previously received peginterferon-based therapy for at least 24 weeks with documented HCV RNA at last measurement and relapsed within 1 year of last taking medication~* Liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection~* Must agree to use 2 forms of effective contraception throughout study (both males and females)~Exclusion Criteria:~* Infection with HIV or non-genotype 1 hepatitis C~* Liver disease not related to hepatitic C infection~* Hepatic decompensation~* Significant laboratory abnormalities or other active diseases~* Pregnant or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMC435 (Type: EXPERIMENTAL): TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 Formulation in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²), inclusive, at screening~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study~* Are nonsmokers, have not smoked for at least 2 months prior to entering the study, and agree not to smoke (cigars, cigarettes, or pipes) or use smokeless tobacco for the duration of the study~Exclusion Criteria:~* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study~* Have previously participated or withdrawn from this study~* Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study~* Had blood loss of more than 450 milliliters (mL) within the last month

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 (Type: EXPERIMENTAL): Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
- Insulin Lispro (Type: ACTIVE_COMPARATOR): Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age at least 18 years of age, or age of consent in the region.~* Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised International System for Staging Lung Cancer criteria of 2010) or recurrent non-small cell lung cancer (NSCLC).~* Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC.~* Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or metastatic non-squamous NSCLC.~Exclusion Criteria:~* Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature.~* Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation that is likely to bleed.~* Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK translocation positive mutations.~* Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if surgical resection for primary disease was performed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab-Pfizer (Type: EXPERIMENTAL): Bevacizumab-Pfizer plus paclitaxel and carboplatin
- Bevacizumab-EU (Type: ACTIVE_COMPARATOR): Bevacizumab-EU plus paclitaxel and carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gender: male and female~* Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis~* Primary HLH patients~* Patient (if ≥ 18 years old), or patient's legal representative(s) must have signed informed consent~Exclusion Criteria:~* Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven rheumatic or neoplastic disease.~* Body weight \< 3 kg.~* Patients treated with biologics within a specific timeframe~* Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections.~* Presence of malignancy.~* Concomitant disease or malformation severely affecting the cardiovascular, pulmonary, liver or renal function

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- NI-0501 (Type: EXPERIMENTAL): NI-0501 administered by IV infusion at a starting dose of 1 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-menopausal woman, between her 18th and 39th birthday, receiving recombinant FSH as stimulation for IVF and/or ICSI~* Subjects who were able to communicate well with the investigator and to comply with the requirements of the entire study~* Subjects who had given written informed consent, prior to treatment, with the understanding that consent may be withdrawn by the subject at any time without prejudice~Exclusion Criteria:~* Subjects who had known allergic reaction against one of the ingredients~* Subjects with enlarged ovaries or cysts unrelated to polycystic ovaries (PCO)~* Subjects with gynaecological bleeding of unknown origin~* Subjects who had ovarian, uterine, or mammary cancer~* Subjects with tumors of the hypothalamus or the pituitary gland

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Gonal-f (Type: EXPERIMENTAL): None
- Puregon (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gender-Responsive Treatment for Women Offenders - 1

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Drug court participant~* At least eighteen (18) years old~* Have had no more than three prior non-violent, non-drug felony convictions~* Do not have a current charge of driving under the influence of alcohol or drugs or a charge of sale or transportation of drugs~Exclusion Criteria:~* Not capable of giving informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Women-Only (Type: EXPERIMENTAL): Substance abuse treatment program for women only
- Mixed-Gender (Type: NO_INTERVENTION): Substance abuse treatment program for both women and men

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genistein in Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients ≥18 years old~* Have pathologically confirmed colon or rectal carcinoma~* Have metastatic (stage IV) disease~* Have a plan by treating physician to receive FOLFOX or FOLFOX-Avastin~* Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2~* Have adequate hematopoietic, hepatic and renal function~  1. Hematopoietic function~     * Hemoglobin ≥10g/dL~    * Absolute Neutrophil Count(ANC) ≥1,500cells/mm2~    * Platelet Count ≥100,000/µL~ 2. Hepatic Function~     * Total bilirubin ≤ 1.5x the upper limit of normal~    * ALT and AST must each be ≤2,5x the upper limits of normal~ 3. Renal Function~     * Estimated creatinine clearance (Clcr) ≥30 mL/minute~* Are not pregnant and do not plan to become pregnant~Exclusion Criteria:~* Prior systemic chemotherapy for metastatic disease~* History of breast cancer, endometrial cancer or ovarian cancer or taking aromatase inhibitors or selective estrogen receptor modulators~* Patients taking MAO-inhibitors~* History of myocardial infarctions or cardiac stent placement less than 1 year before recruitment into the study~* Unable to give informed consent or comply with clinical trial requirements~* Uncontrolled hypertension~* History of clinically significant GI bleeding within prior 2 months prior to enrollment~* Presence of GI fistula~* Prior history of bowel perforation~* History of CNS thrombotic/embolic or ischemic events~* Have past or current, acute or chronic concurrent medical condition/illness or therapy that, in the opinion of the investigator, would make the subject unsuitable for the clinical trial or unable to comply with the follow up visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genistein (Type: EXPERIMENTAL): Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient suffers from recurrent MDD as the primary diagnosis according to DSM-IVTR™ criteria. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI)~* The patient has a MADRS total score ≥26~* The patient has a CGI-S score ≥4~* The reported duration of the current MDE is ≥3 months.~Other inclusion criteria may apply.~Exclusion Criteria:~- The patient meets any of the exclusion criteria listed in the protocol or, in the investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Lu AA21004) (Type: EXPERIMENTAL): None
- Venlafaxine extended release (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female subjects, 55 years of age and older.~2. Diagnosis of active, subfoveal choroidal neovascular membranes (CNVM) due to age related macular degeneration (AMD)~3. Visual acuity from 20/25 to 20/400 in the study eye.~Exclusion Criteria:~1. Subjects who have received corticosteroids via any route in the past 30 days.~2. In the opinion of the investigator, patient is known to be a steroid-responder.~3. Subjects with a history of uncontrolled glaucoma (Primary or Secondary)~4. History of ocular surgery (invasive or non-invasive) in the past 90 days~5. Intravitreal treatment with an anti-VEGF agent e.g. bevacizumab, ranibizumab, or pegaptanib within 30 days of the enrollment (Day 0) examination.~6. Patients requiring systemic steroids (greater than 15 mg daily by mouth) or systemic immunomodulatory agents.~7. Active ocular or periocular infection (i.e., bacterial, viral, parasitic or fungal) in either eye or a history of herpetic ocular infection in either eye.~8. Media opacity in the study eye precluding observation or photography of the fundus.~9. Any other clinically significant medical or psychological condition that, in the opinion of the Investigator, would jeopardize the safety of the patient or affect the validity of the study results.~10. Participation in a clinical trial of an investigational drug or device within 30 days of the screening visit.~11. Known history of allergy to corticosteroids.~12. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IBI-20089/Lucentis (Type: EXPERIMENTAL): Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete